Aethlon Medical EBIT

The latest EBIT for AEMD is $-1.5B as of March 2026. That compares with $-5.5B in the prior-year period — up 73.0% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Aethlon Medical's historical trend and sector peers before judging valuation or financial health.

Over the past year, AEMD's EBIT moved from $-5.5B to $-1.5B — a 73.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Aethlon Medical's operating scale or balance-sheet position.

Against Healthcare companies, AEMD currently prints $-1.5B for EBIT, while the sector average sits near $22B. That is roughly 106.6% below the sector mean. Large gaps often invite a closer look at Aethlon Medical's growth, margins, and balance sheet.

A EBIT figure of $-1.5B for AEMD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting AEMD's EBIT ($-1.5B), review year-over-year change from $-5.5B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.